Work Here?
About Natera
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Austin, Texas
Founded
2004
Overview
Company Historically Provides H1B Sponsorship
Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their core technology involves analyzing cell-free DNA (cfDNA) from blood samples to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT for prenatal screening, along with genetic counseling services. The company's goal is to improve patient care through precise genetic insights.
Simplify's Take
What believers are saying
- Growing demand for non-invasive cancer monitoring boosts Natera's Signatera test adoption.
- Telehealth expansion supports Natera's remote genetic counseling services.
- Rising organ transplant procedures increase demand for Natera's Prospera test.
What critics are saying
- Increased competition from companies like Lantheus may impact Natera's market share.
- Natera's CFO selling stock could indicate potential internal concerns.
- Reliance on insurance reimbursements poses a risk if healthcare policies change.
What makes Natera unique
- Natera specializes in cell-free DNA testing for prenatal, oncology, and transplant health.
- The company offers the unique Signatera test for personalized cancer monitoring.
- Natera's Prospera Heart test uses a novel Donor Quantity Score for transplant rejection detection.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1338.2M
Above
Industry Average
Funded Over
10 Rounds
Lightspeed Venture Partners
Founders FundBenefits
Flexible medical plans
Investment options
Time off
Workplace perks
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 5%Last week, Natera (NasdaqGS:NTRA) announced a strategic expansion of its Board of Directors with the appointment of Monica Bertagnolli.
Natera launches HEROES trial for breast cancer treatment.
Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m
Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).
Natera is Hiring for 199 Jobs on Simplify!
Find jobs on Simplify and start your career today
Software Engineering
13 Open Roles
QA & Testing
9 Open Roles
AI & Machine Learning
5 Open Roles
Data & Analytics
4 Open Roles
Sales & Solution Engineering
2 Open Roles
Engineering Management
1 Open Roles
DevOps & Infrastructure
1 Open Roles
Architecture & Civil Engineering
1 Open Roles
UI/UX & Design
1 Open Roles
People Also Viewed
Discover companies similar to Natera
About Natera
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Austin, Texas
Founded
2004
Natera is Hiring for 199 Jobs on Simplify!
Find jobs on Simplify and start your career today
Software Engineering
13 Open Roles
QA & Testing
9 Open Roles
AI & Machine Learning
5 Open Roles
Data & Analytics
4 Open Roles
Sales & Solution Engineering
2 Open Roles
Engineering Management
1 Open Roles
DevOps & Infrastructure
1 Open Roles
Architecture & Civil Engineering
1 Open Roles
UI/UX & Design
1 Open Roles
People Also Viewed
Discover companies similar to Natera